Global Live Attenuated Vaccines Market Size By Type (Bacterial, Viral), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Live Attenuated Vaccines Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 9.4 billion by 2031, expanding at a CAGR of 6.5% during the forecast period (2023–2031). Live attenuated vaccines contain weakened forms of pathogens that stimulate a strong and long-lasting immune response. These vaccines are increasingly used in preventing infectious diseases such as measles, mumps, rubella, varicella, and yellow fever. The market is driven by rising immunization coverage globally, increasing prevalence of infectious diseases, and government-led vaccination initiatives. Ongoing innovations in vaccine delivery mechanisms and expanded R&D funding are further propelling market growth.

Drivers

1. Rising Prevalence of Infectious Diseases

The increasing burden of vaccine-preventable diseases such as influenza, rotavirus, and measles is one of the key drivers boosting the demand for live attenuated vaccines globally.

2. Government Immunization Programs

Public health initiatives and immunization campaigns by organizations like WHO, UNICEF, and GAVI are playing a pivotal role in expanding access to live attenuated vaccines, particularly in low- and middle-income countries.

3. Strong Immunological Response and Long-Term Protection

Live attenuated vaccines typically offer stronger immunity and often require fewer doses compared to inactivated vaccines, which makes them more efficient for large-scale immunization efforts.

Restraints

1. Cold Chain Logistics

Live attenuated vaccines require strict temperature-controlled storage and transportation to remain effective, presenting logistical challenges, particularly in remote and underdeveloped regions.

2. Contraindications in Immunocompromised Individuals

These vaccines are not recommended for individuals with weakened immune systems, such as those undergoing chemotherapy or with HIV/AIDS, limiting their usage in certain populations.

Opportunity

1. Emerging Markets and Disease Outbreak Preparedness

There is substantial potential for market expansion in developing regions where immunization coverage is still growing. Additionally, pandemic preparedness and surveillance programs are opening new avenues for vaccine development and deployment.

2. Development of Combination Vaccines

Technological advancements allowing the combination of multiple live attenuated vaccines into a single dose offer convenience, improved compliance, and broadened disease protection, enhancing market growth prospects.

Market by System Type Insights

By vaccine type, the viral vaccines segment accounted for the largest market share in 2023. Vaccines for measles, mumps, rubella (MMR), and varicella have widespread adoption due to their proven efficacy and inclusion in national immunization schedules globally. The bacterial vaccines segment is also growing, driven by increasing research on live attenuated bacterial strains for diseases such as tuberculosis (BCG vaccine).

Market by End-Use Insights

In terms of end-use, the pediatric segment dominated the market in 2023, owing to mandatory childhood immunization programs in both developed and developing countries. The adult segment is expected to witness notable growth due to increasing awareness of adult vaccinations and growing adoption of travel-related and seasonal vaccines.

Market by Regional Insights

Asia-Pacific emerged as the leading region in 2023, driven by large population bases, increasing healthcare investments, and expanding immunization coverage in countries like India and China. North America is also a significant market, supported by high vaccination rates, established healthcare infrastructure, and substantial government funding. Africa and Latin America are anticipated to witness robust growth due to GAVI and WHO-sponsored immunization initiatives.

Competitive Scenario

Key players operating in the Global Live Attenuated Vaccines Market include:

GlaxoSmithKline plc

Merck & Co., Inc.

Sanofi

Serum Institute of India

Bharat Biotech

Pfizer Inc.

CSL Limited

AstraZeneca

Bavarian Nordic

Emergent BioSolutions Inc.

These companies are actively investing in R&D, expanding production capabilities, and forming strategic partnerships to meet global demand. For example:

In 2023, Merck & Co. announced clinical trials for a next-generation combination live attenuated vaccine targeting multiple viral strains in one shot.

In 2024, Bharat Biotech received WHO prequalification for a newly developed live attenuated rotavirus vaccine targeting developing markets.

Sanofi partnered with local manufacturers in Africa in 2025 to boost regional supply of live vaccines against yellow fever and measles.

Scope of Work – Global Live Attenuated Vaccines Market

Key Market Developments

March 2023: GSK launched a hexavalent combination vaccine using live attenuated viral components in European markets.

July 2024: Pfizer announced the expansion of its vaccine production facility in Belgium to meet increasing demand in global immunization programs.

January 2025: Serum Institute of India initiated a partnership with the African Union to locally produce live attenuated vaccines, reducing dependency on imports.

FAQs

1. What is the current market size of the Global Live Attenuated Vaccines Market?

The market size in 2023 was USD 5.6 billion.

2. What is the major growth driver of the Global Live Attenuated Vaccines Market?

The primary growth driver is the increasing prevalence of infectious diseases and government-led immunization initiatives.

3. Which is the largest region during the forecast period in the Global Live Attenuated Vaccines Market?

Asia-Pacific is projected to remain the largest region due to high population and increasing immunization coverage.

4. Which segment accounted for the largest market share in the Global Live Attenuated Vaccines Market?

The viral vaccines segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Live Attenuated Vaccines Market?

Key players include GlaxoSmithKline, Merck, Sanofi, Serum Institute of India, Pfizer, and Bharat Biotech.